BioAro’s UAE Subsidiary Secures Drug Store (Medical Warehouse) License, Expanding Market Entry Opportunities for Global Health and MedTech Companies
Dubai, United Arab Emirates – February, 2026 – BioAro Inc. announces that its UAE subsidiary has received official approval for a Drug Store (Medical Warehouse) License in the United Arab Emirates, authorizing the import, storage, and distribution of medicines, medical devices, and healthcare products nationwide.
This milestone strengthens BioAro’s operational footprint and creates expanded opportunities for pharmaceutical manufacturers, nutraceutical brands, and medical device companies seeking structured entry into the UAE healthcare market.
Although companies may obtain product approvals from the Ministry of Health and Prevention (MOHAP), approval alone does not permit importation or commercial distribution. UAE regulations require these activities to be conducted through a licensed Drug Store entity authorized to manage compliant importation, customs clearance, storage, and distribution.
BioAro’s license enables the company to import regulated medical products, manage customs clearance, provide compliant warehousing including temperature-controlled storage where required, and distribute products to hospitals, clinics, and pharmacies across the UAE in alignment with Good Distribution Practice standards.
For international healthcare ventures, the UAE represents a strategic gateway market; however, regulatory navigation and operational setup can delay commercialization. Through its licensed Drug Store platform, BioAro provides integrated support that accelerates compliant market entry.
In parallel, Kapoor Wealth Partners provides regulatory advisory and structured market entry support, assisting companies with product classification, dossier preparation, submission management, health authority coordination, and post-approval compliance strategy. Together, the combined capabilities provide a streamlined pathway from regulatory clearance to compliant importation and distribution.
This achievement follows BioAro’s recent UAE approvals for its proprietary BioActive Longevity Stack, including Longevity+™,CellOmega+™, andCreaGen™, which include age- and sex-specific compositions incorporating targeted micronutrients. Securing these approvals validated BioAro’s regulatory, labeling, and compliance framework within the UAE system and positioned the company for broader operational expansion.
With the Drug Store license now secured, BioAro transitions into a licensed healthcare distribution platform capable of supporting third-party manufacturers entering the UAE market.
Dr. Anmol S. Kapoor, Founder of BioAro, stated, “Securing our Drug Store license in the UAE marks a critical step in building compliant healthcare infrastructure in the region. Many companies obtain MOHAP product approvals but lack the licensed entity required to import, warehouse, and distribute within the country. The UAE regulatory environment is robust and structured to ensure patient safety and product quality, and navigating classification pathways, documentation standards, pricing frameworks, and authority engagement protocols is essential for international companies. Through Kapoor Wealth Partners’ regulatory advisory expertise and BioAro’s licensed Drug Store and distribution capabilities, we are creating a seamless pathway for global health innovators to responsibly and efficiently enter the UAE market. Together, we provide clarity, compliance, and continuity from regulatory strategy through to commercial execution, with the goal of establishing long-term, compliant, and scalable healthcare operations within the Emirates.”
The UAE continues to invest in healthcare innovation and life sciences as part of its broader economic diversification strategy. BioAro’s expanded licensing status aligns with national priorities focused on strengthening supply chain resilience and enabling responsible access to advanced therapeutics and health technologies.
